Trade. Carmat, manufacturer of artificial hearts, declares bankruptcy.

His heartbeat is slowing. Carmat, the French manufacturer of a temporary artificial heart for patients with severe heart failure, announced Monday that it had ceased payments and was filing for receivership.

The company, which warned ten days ago that it was at risk of running out of money, will "request the opening of a judicial recovery procedure with the Versailles Economic Affairs Court."

Pending the court's decision, "expected in the next few days," Carmat has requested the suspension of its stock market price "from Monday, June 30, 2025," before the markets open.

A donation campaign... insufficient

Founded in 2008, the company had said it needed to raise at least €3.5 million by June 30, and around €20 million by the end of the year. It had launched a fundraising campaign to ensure its continued operations .

"Despite its continued efforts, the company has not yet managed to secure such additional cash or new financing," said Carmat, which "continues to explore all options that would allow it to continue operating."

The opening of a judicial recovery procedure would constitute, according to her, "the most appropriate framework to facilitate this pursuit".

Patients will be followed

Carmat assures that "whatever the court's decision," it "will strive to continue to provide support to patients currently benefiting from the Aeson artificial heart."

Carmat's Aeson artificial heart is designed for patients suffering from end-stage heart failure awaiting a transplant. To date, 122 patients have been treated with Aeson. The company had voluntarily suspended implantations between the end of 2021 and October 2022 to make improvements to the device following malfunctions that cost the lives of two patients.